{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:35Z","timestamp":1791312095595,"version":"4.3.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-025-00938-1","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:56:50Z","timestamp":1759157810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers"],"prefix":"10.1186","volume":"25","author":[{"given":"Kang","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"1","key":"938_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bju.15842","volume":"131","author":"SS Djurhuus","year":"2023","unstructured":"Djurhuus SS, Simonsen C, Toft BG, Thomsen SN, Wiels\u00f8e S, R\u00f8der MA. Exercise training to increase tumour natural killer-cell infiltration in men with localised prostate cancer: a randomised controlled trial. BJU Int. 2023;131(1):116\u201324.","journal-title":"BJU Int"},{"issue":"3","key":"938_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"938_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00432-023-05574-5","volume":"150","author":"YF Zhang","year":"2024","unstructured":"Zhang YF, Zhou C, Guo S, Wang C, Yang J, Yang ZJ, Wang R, Zhang X, Zhou FH. Deep learning algorithm-based multimodal MRI radiomics and pathomics data improve prediction of bone metastases in primary prostate cancer. J Cancer Res Clin Oncol. 2024;150(2):78.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"938_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/path.5887","volume":"257","author":"J Cyrta","year":"2022","unstructured":"Cyrta J, Prandi D. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. J Pathol. 2022;257(3):274\u201384.","journal-title":"J Pathol"},{"issue":"4","key":"938_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate Cancer-Updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and Meta-analysis. Eur Urol. 2020;77(4):403\u201317.","journal-title":"Eur Urol"},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"100588","DOI":"10.1016\/j.ejro.2024.100588","volume":"13","author":"N Nishioka","year":"2024","unstructured":"Nishioka N, Fujima N, Tsuneta S, Yoshikawa M, Kimura R, Sakamoto K, Kato F, Miyata H, Kikuchi H, Matsumoto R, et al. Enhancing the image quality of prostate diffusion-weighted imaging in patients with prostate cancer through model-based deep learning reconstruction. Eur J Radiol Open. 2024;13:100588.","journal-title":"Eur J Radiol Open"},{"issue":"Supplement","key":"938_CR7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.4103\/jcrt.JCRT_172_18","volume":"15","author":"H Abdollahi","year":"2019","unstructured":"Abdollahi H, Mahdavi SR, Shiri I, Mofid B, Bakhshandeh M, Rahmani K. Magnetic resonance imaging radiomic feature analysis of radiation-induced femoral head changes in prostate cancer radiotherapy. J Cancer Res Ther. 2019;15(Supplement):S11\u20139.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"938_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2008.11.013","volume":"91","author":"L Sullivan","year":"2009","unstructured":"Sullivan L, Williams SG, Tai KH, Foroudi F, Cleeve L, Duchesne GM. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2009;91(2):232\u20136.","journal-title":"Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol"},{"issue":"1106","key":"938_CR9","doi-asserted-by":"publisher","first-page":"20190760","DOI":"10.1259\/bjr.20190760","volume":"93","author":"YM Tsang","year":"2020","unstructured":"Tsang YM, Vignarajah D, McWilliam A, Tharmalingam H, Lowe G, Choudhury A, Hoskin P. A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer. Br J Radiol. 2020;93(1106):20190760.","journal-title":"Br J Radiol"},{"issue":"6","key":"938_CR10","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/j.clon.2021.12.020","volume":"34","author":"H Tharmalingam","year":"2022","unstructured":"Tharmalingam H, Tsang YM, Alonzi R, Beasley W, Taylor NJ, McWilliam A, Padhani A, Choudhury A, Hoskin PJ. Changes in magnetic resonance imaging radiomic features in response to androgen deprivation therapy in patients with Intermediate- and High-risk prostate cancer. Clin Oncol (R Coll Radiol (G B)). 2022;34(6):e246\u201353.","journal-title":"Clin Oncol (R Coll Radiol (G B))"},{"issue":"1","key":"938_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/jmri.25335","volume":"45","author":"K Gnep","year":"2017","unstructured":"Gnep K, Fargeas A, Guti\u00e9rrez-Carvajal RE, Commandeur F, Mathieu R, Ospina JD, Rolland Y, Rohou T, Vincendeau S, Hatt M, et al. Haralick textural features on T(2) -weighted MRI are associated with biochemical recurrence following radiotherapy for peripheral zone prostate cancer. J Magn Reson Imaging: JMRI. 2017;45(1):103\u201317.","journal-title":"J Magn Reson Imaging: JMRI"},{"issue":"6","key":"938_CR12","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/jmri.26178","volume":"48","author":"R Shiradkar","year":"2018","unstructured":"Shiradkar R, Ghose S, Jambor I, Taimen P, Ettala O, Purysko AS. Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: preliminary findings. J Magn Reson Imaging: JMRI. 2018;48(6):1626\u201336.","journal-title":"J Magn Reson Imaging: JMRI"},{"issue":"4","key":"938_CR13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/jmri.27138","volume":"52","author":"GM Zhang","year":"2020","unstructured":"Zhang GM, Han YQ, Wei JW, Qi YF. Radiomics based on MRI as a biomarker to guide therapy by predicting upgrading of prostate cancer from biopsy to radical prostatectomy. J Magn Reson Imaging: JMRI. 2020;52(4):1239\u201348.","journal-title":"J Magn Reson Imaging: JMRI"},{"key":"938_CR14","doi-asserted-by":"publisher","first-page":"103163","DOI":"10.1016\/j.ebiom.2020.103163","volume":"63","author":"L Li","year":"2021","unstructured":"Li L, Shiradkar R, Leo P, Algohary A, Fu P, Tirumani SH, Mahran A, Buzzy C, Obmann VC, Mansoori B, et al. A novel imaging based nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI. EBioMedicine. 2021;63:103163.","journal-title":"EBioMedicine"},{"issue":"2","key":"938_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ijrobp.2019.06.2504","volume":"105","author":"SOS Osman","year":"2019","unstructured":"Osman SOS, Leijenaar RTH, Cole AJ, Lyons CA, Hounsell AR, Prise KM, O\u2019Sullivan JM, Lambin P, McGarry CK, Jain S. Computed Tomography-based radiomics for risk stratification in prostate cancer. Int J Radiat Oncol Biol Phys. 2019;105(2):448\u201356.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1101","key":"938_CR16","doi-asserted-by":"publisher","first-page":"20190286","DOI":"10.1259\/bjr.20190286","volume":"92","author":"E Acar","year":"2019","unstructured":"Acar E, Leblebici A, Ellidokuz BE, Ba\u015fb\u0131nar Y, Kaya G. Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study. Br J Radiol. 2019;92(1101):20190286.","journal-title":"Br J Radiol"},{"issue":"13","key":"938_CR17","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1007\/s00259-020-04864-1","volume":"47","author":"JC Peeken","year":"2020","unstructured":"Peeken JC, Shouman MA, Kroenke M, Rauscher I, Maurer T, Gschwend JE, Eiber M, Combs SE. A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients. Eur J Nucl Med Mol Imaging. 2020;47(13):2968\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"938_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11547-019-01082-0","volume":"125","author":"S Mostafaei","year":"2020","unstructured":"Mostafaei S, Abdollahi H, Kazempour Dehkordi S, Shiri I, Razzaghdoust A, Zoljalali Moghaddam SH, Saadipoor A, Koosha F, Cheraghi S, Mahdavi SR. CT imaging markers to improve radiation toxicity prediction in prostate cancer radiotherapy by stacking regression algorithm. Radiol Med. 2020;125(1):87\u201397.","journal-title":"Radiol Med"},{"issue":"1","key":"938_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/pros.24442","volume":"83","author":"W Ou","year":"2023","unstructured":"Ou W, Lei J. Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies. Prostate. 2023;83(1):109\u201318.","journal-title":"Prostate"},{"key":"938_CR20","doi-asserted-by":"publisher","first-page":"610785","DOI":"10.3389\/fonc.2021.610785","volume":"11","author":"L Liang","year":"2021","unstructured":"Liang L, Zhi X, Sun Y, Li H, Wang J, Xu J, Guo J. A nomogram based on a multiparametric ultrasound radiomics model for discrimination between malignant and benign prostate lesions. Front Oncol. 2021;11:610785.","journal-title":"Front Oncol"},{"issue":"2","key":"938_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00330-019-06436-w","volume":"30","author":"RR Wildeboer","year":"2020","unstructured":"Wildeboer RR, Mannaerts CK, van Sloun RJG, Bud\u00e4us L, Tilki D, Wijkstra H, Salomon G, Mischi M. Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics. Eur Radiol. 2020;30(2):806\u201315.","journal-title":"Eur Radiol"},{"issue":"1","key":"938_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1515\/bmt-2018-0136","volume":"65","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Xiong J, Cai Y, Shi J, Xu S, Zhang B. Multimodal feature learning and fusion on B-mode ultrasonography and sonoelastography using point-wise gated deep networks for prostate cancer diagnosis. Biomed Tech (Berl). 2020;65(1):87\u201398.","journal-title":"Biomed Tech (Berl)"},{"issue":"2","key":"938_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"issue":"6","key":"938_CR24","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00259-020-05111-3","volume":"48","author":"C Zamboglou","year":"2021","unstructured":"Zamboglou C, Bettermann AS, Gratzke C, Mix M, Ruf J, Kiefer S, Jilg CA, Benndorf M, Spohn S, Fassbender TF, et al. Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(6):1987\u201397.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"938_CR25","doi-asserted-by":"crossref","unstructured":"Feliciani G, Celli M. Radiomics analysis on [(68)Ga]Ga-PSMA-11 PET and MRI-ADC for the prediction of prostate cancer ISUP grades: preliminary results of the BIOPSTAGE trial. Cancers (Basel) 2022, 14(8).","DOI":"10.3390\/cancers14081888"},{"issue":"3","key":"938_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/tomography7030027","volume":"7","author":"A Erle","year":"2021","unstructured":"Erle A, Moazemi S. Evaluating a machine learning tool for the classification of pathological uptake in Whole-Body PSMA-PET-CT scans. Tomography. 2021;7(3):301\u201312.","journal-title":"Tomography"},{"issue":"2","key":"938_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00259-020-04971-z","volume":"48","author":"MCF Cysouw","year":"2021","unstructured":"Cysouw MCF, Jansen BHE, van de Brug T, Oprea-Lager DE, Pfaehler E, de Vries BM, van Moorselaar RJA, Hoekstra OS, Vis AN, Boellaard R. Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):340\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"938_CR28","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.1038\/s41598-025-96279-x","volume":"15","author":"VHE Chen","year":"2025","unstructured":"Chen VHE, Tay JK, Gurung R, Nair S, Tay DJW, Tan KS, Foo RSY, Tambyah PA. ACE2 and TMPRSS2 gene expression is reduced acutely in SARS-CoV-2 patients but returns to normal with recovery. Sci Rep. 2025;15(1):12828.","journal-title":"Sci Rep"},{"issue":"5748","key":"938_CR29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1117679","volume":"310","author":"SA Tomlins","year":"2005","unstructured":"Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Sci (New York NY). 2005;310(5748):644\u20138.","journal-title":"Sci (New York NY)"},{"issue":"10","key":"938_CR30","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ijc.35279","volume":"156","author":"CB McGrath","year":"2025","unstructured":"McGrath CB, Shreves AH. Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors. Int J Cancer. 2025;156(10):1898\u2013908.","journal-title":"Int J Cancer"},{"issue":"6","key":"938_CR31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.molcel.2020.07.028","volume":"79","author":"Z Hong","year":"2020","unstructured":"Hong Z, Zhang W, Ding D, Huang Z, Yan Y, Cao W, Pan Y, Hou X, Weroha SJ, Karnes RJ, et al. DNA damage promotes TMPRSS2-ERG oncoprotein destruction and prostate cancer suppression via signaling converged by GSK3\u03b2 and WEE1. Mol Cell. 2020;79(6):1008\u2013e10231004.","journal-title":"Mol Cell"},{"issue":"1","key":"938_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/pros.23918","volume":"80","author":"L Shao","year":"2020","unstructured":"Shao L, Kahraman N, Yan G, Wang J, Ozpolat B, Ittmann M. Targeting the TMPRSS2\/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2020;80(1):65\u201373.","journal-title":"Prostate"},{"issue":"5","key":"938_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","volume":"70","author":"L Van Neste","year":"2016","unstructured":"Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, et al. Detection of High-grade prostate cancer using a urinary molecular Biomarker-Based risk score. Eur Urol. 2016;70(5):740\u20138.","journal-title":"Eur Urol"},{"issue":"1","key":"938_CR34","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1038\/s41467-021-24380-6","volume":"12","author":"M Zoma","year":"2021","unstructured":"Zoma M, Curti L, Shinde D. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer. Nat Commun. 2021;12(1):4147.","journal-title":"Nat Commun"},{"issue":"5","key":"938_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/bju.12120","volume":"111","author":"D Hossain","year":"2013","unstructured":"Hossain D, Bostwick DG. Significance of the TMPRSS2:ERG gene fusion in prostate cancer. BJU Int. 2013;111(5):834\u20135.","journal-title":"BJU Int"},{"issue":"4","key":"938_CR36","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1039\/D0FO02382E","volume":"12","author":"ZL Li","year":"2021","unstructured":"Li ZL, Mi J, Lu L, Luo Q, Liu X, Yan YM, Jin B, Cao YL, Zeng XX, Ran LW. The main anthocyanin monomer of lycium ruthenicum Murray induces apoptosis through the ROS\/PTEN\/PI3K\/Akt\/caspase 3 signaling pathway in prostate cancer DU-145 cells. Food Funct. 2021;12(4):1818\u201328.","journal-title":"Food Funct"},{"issue":"3","key":"938_CR37","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2174\/1871520620666200811113549","volume":"21","author":"R Serttas","year":"2021","unstructured":"Serttas R, Koroglu C, Erdogan S. Eupatilin inhibits the proliferation and migration of prostate cancer cells through modulation of PTEN and NF-\u03baB signaling. Anti-cancer Agents Med Chem. 2021;21(3):372\u201382.","journal-title":"Anti-cancer Agents Med Chem"},{"issue":"1","key":"938_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/aja.aja_39_21","volume":"24","author":"JY Zhang","year":"2022","unstructured":"Zhang JY, Kong YY, Wang QF, Yang YJ, Liu Z, Lin N, Ye DW, Dai B. Prognostic value of PTEN in de Novo diagnosed metastatic prostate cancer. Asian J Androl. 2022;24(1):50\u20135.","journal-title":"Asian J Androl"},{"issue":"23","key":"938_CR39","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11428\u201336.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"938_CR40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298\u2013305.","journal-title":"Nat Med"},{"key":"938_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/978-3-030-32656-2_13","volume":"1210","author":"DL Burkhart","year":"2019","unstructured":"Burkhart DL, Morel KL, Sheahan AV, Richards ZA, Ellis L. The role of RB in prostate cancer progression. Adv Exp Med Biol. 2019;1210:301\u201318.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"938_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","volume":"76","author":"AA Hamid","year":"2019","unstructured":"Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol. 2019;76(1):89\u201397.","journal-title":"Eur Urol"},{"issue":"6","key":"938_CR43","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1007\/s11033-019-05093-y","volume":"46","author":"MB Bat\u0131r","year":"2019","unstructured":"Bat\u0131r MB, \u015eahin E, \u00c7am FS. Evaluation of the CRISPR\/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3. Mol Biol Rep. 2019;46(6):6471\u201384.","journal-title":"Mol Biol Rep"},{"issue":"6","key":"938_CR44","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","volume":"25","author":"B De Laere","year":"2019","unstructured":"De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic Castration-Resistant prostate cancer. Clin Cancer Res. 2019;25(6):1766\u201373.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"938_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2217\/bmm-2019-0141","volume":"13","author":"J Sun","year":"2019","unstructured":"Sun J, Zhang K, Cai Z, Li K, Zhao C, Fan C, Wang J. Identification of critical pathways and hub genes in TP53 mutation prostate cancer by bioinformatics analysis. Biomark Med. 2019;13(10):831\u201340.","journal-title":"Biomark Med"},{"issue":"1","key":"938_CR46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jnci\/djab147","volume":"114","author":"DR Barnes","year":"2022","unstructured":"Barnes DR, Silvestri V. Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores. J Natl Cancer Inst. 2022;114(1):109\u201322.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"938_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","volume":"66","author":"EK Bancroft","year":"2014","unstructured":"Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66(3):489\u201399.","journal-title":"Eur Urol"},{"issue":"22","key":"938_CR48","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O. Olaparib for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"11","key":"938_CR49","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","volume":"27","author":"H Tukachinsky","year":"2021","unstructured":"Tukachinsky H, Madison RW. Genomic analysis of Circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin Cancer Res. 2021;27(11):3094\u2013105.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"938_CR50","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3346\/jkms.2017.32.2.377","volume":"32","author":"WH Song","year":"2017","unstructured":"Song WH, Kim SH. Prostate cancer in a patient with a family history of BRCA mutation: a case report and literature review. J Korean Med Sci. 2017;32(2):377\u201381.","journal-title":"J Korean Med Sci"},{"issue":"9","key":"938_CR51","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41422-019-0204-1","volume":"29","author":"B Xu","year":"2019","unstructured":"Xu B, Song B, Lu X, Kim J, Hu M, Zhao JC, Yu J. Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression. Cell Res. 2019;29(9):773\u20135.","journal-title":"Cell Res"},{"issue":"2","key":"938_CR52","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/JCI122367","volume":"129","author":"B Song","year":"2019","unstructured":"Song B, Park SH, Zhao JC, Fong KW, Li S, Lee Y, Yang YA, Sridhar S, Lu X, Abdulkadir SA, et al. Targeting FOXA1-mediated repression of TGF-\u03b2 signaling suppresses castration-resistant prostate cancer progression. J Clin Investig. 2019;129(2):569\u201382.","journal-title":"J Clin Investig"},{"issue":"5","key":"938_CR53","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41375-024-02194-x","volume":"38","author":"J Ma","year":"2024","unstructured":"Ma J, Liu YC, Voss RK, Ma J, Palagani A, Caldwell E. Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 fusion. Leukemia. 2024;38(5):981\u201390.","journal-title":"Leukemia"},{"issue":"10","key":"938_CR54","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s11255-018-1964-0","volume":"50","author":"Z Cai","year":"2018","unstructured":"Cai Z, Chen W, Zhang J, Li H. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer. Int Urol Nephrol. 2018;50(10):1753\u201364.","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"938_CR55","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701\u201311.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"938_CR56","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"The Molecular Taxonomy of Primary Prostate Cancer","year":"2015","unstructured":"The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011\u201325.","journal-title":"Cell"},{"issue":"6","key":"938_CR57","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.2279","volume":"44","author":"CE Barbieri","year":"2012","unstructured":"Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44(6):685\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"938_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12894-023-01323-5","volume":"23","author":"T Aizawa","year":"2023","unstructured":"Aizawa T, Maebayashi T, Ishibashi N, Sakaguchi M, Sato A, Yamaguchi K. Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery. BMC Urol. 2023;23(1):157.","journal-title":"BMC Urol"},{"issue":"41","key":"938_CR59","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.3346\/jkms.2020.35.e342","volume":"35","author":"JH Chung","year":"2020","unstructured":"Chung JH, Yu J. Strategy for prostate cancer patients with low prostate specific antigen level (2.5 to 4.0 ng\/mL). J Korean Med Sci. 2020;35(41):e342.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"938_CR60","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/bju.16211","volume":"133","author":"PC Albertsen","year":"2024","unstructured":"Albertsen PC, Bjerner LJ, Pasovic L, M\u00fcller S, Foss\u00e5 S, Carlsson SV, Oldenburg J. Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge. BJU Int. 2024;133(1):104\u201311.","journal-title":"BJU Int"},{"issue":"07","key":"938_CR61","first-page":"1105","volume":"40","author":"W Du","year":"2025","unstructured":"Du W, Li ML, Tao J. [Association between serum ferr, fPSA and disease progression of prostate cancer and predictive value for poor prognosis]. Practical J Cancer. 2025;40(07):1105\u20138.","journal-title":"Practical J Cancer"},{"key":"938_CR62","doi-asserted-by":"publisher","first-page":"184945441772015","DOI":"10.1177\/1849454417720151","volume":"6","author":"AG Guerrico","year":"2017","unstructured":"Guerrico AG, Hillman D, Karnes J, Davis B, Gaston S, Klee G. Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circulating Biomarkers. 2017;6:1849454417720151.","journal-title":"J Circulating Biomarkers"},{"issue":"42","key":"938_CR63","doi-asserted-by":"publisher","first-page":"e12806","DOI":"10.1097\/MD.0000000000012806","volume":"97","author":"Z Mao","year":"2018","unstructured":"Mao Z, Ji A, Yang K, He W, Hu Y, Zhang Q, Zhang D, Xie L. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer. Medicine. 2018;97(42):e12806.","journal-title":"Medicine"},{"issue":"16","key":"938_CR64","first-page":"3008","volume":"30","author":"F Lai","year":"2022","unstructured":"Lai F, Huang CY, Qian YL. [Clinical value of combined detection of serum hK2, AMACR and PSA in the diagnosis and prognosis of prostate cancer]. Mod Oncol. 2022;30(16):3008\u201313.","journal-title":"Mod Oncol"},{"issue":"02","key":"938_CR65","first-page":"262","volume":"37","author":"YF Li","year":"2025","unstructured":"Li YF, Wang W, Zhang L. [Diagnostic value of mp-MRI quantitative parameters combined with serum EPCA-2 and PSA expression levels for extracapsular extension in prostate cancer]. Western Med. 2025;37(02):262\u20136.","journal-title":"Western Med"},{"issue":"6","key":"938_CR66","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1158\/1055-9965.EPI-08-1173","volume":"18","author":"OB Goodman Jr","year":"2009","unstructured":"Goodman OB Jr., Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prevention: Publication Am Association Cancer Res Cosponsored Am Soc Prev Oncol. 2009;18(6):1904\u201313.","journal-title":"Cancer Epidemiol Biomarkers Prevention: Publication Am Association Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"1","key":"938_CR67","first-page":"24","volume":"21","author":"M Maas","year":"2017","unstructured":"Maas M, Hegemann M, Rausch S, Bedke J, Stenzl A, Todenh\u00f6fer T. Circulating tumor cells and their role in prostate cancer. Asian J Androl. 2017;21(1):24\u201331.","journal-title":"Asian J Androl"},{"issue":"12","key":"938_CR68","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1158\/1078-0432.CCR-10-2650","volume":"17","author":"DC Danila","year":"2011","unstructured":"Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011;17(12):3903\u201312.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"938_CR69","first-page":"277","volume":"4","author":"M Wilbaux","year":"2015","unstructured":"Wilbaux M, Tod M, De Bono J, Lorente D, Mateo J, Freyer G, You B, H\u00e9nin E. A joint model for the kinetics of CTC count and PSA concentration during treatment in metastatic Castration-Resistant prostate cancer. CPT: Pharmacometrics Syst Pharmacol. 2015;4(5):277\u201385.","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"938_CR70","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.2147\/CMAR.S170380","volume":"11","author":"YT Lu","year":"2019","unstructured":"Lu YT, Delijani K, Mecum A, Goldkorn A. Current status of liquid biopsies for the detection and management of prostate cancer. Cancer Manage Res. 2019;11:5271\u201391.","journal-title":"Cancer Manage Res"},{"issue":"5","key":"938_CR71","doi-asserted-by":"publisher","first-page":"e235211","DOI":"10.1016\/j.urolonc.2015.12.003","volume":"34","author":"CP Meyer","year":"2016","unstructured":"Meyer CP, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, Riethdorf S, Steuber T. Limited prognostic value of preoperative Circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urol Oncol. 2016;34(5):e235211\u2013236.","journal-title":"Urol Oncol"},{"issue":"2","key":"938_CR72","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000356251","volume":"7","author":"KK Khurana","year":"2013","unstructured":"Khurana KK, Grane R, Borden EC, Klein EA. Prevalence of Circulating tumor cells in localized prostate cancer. Curr Urol. 2013;7(2):65\u20139.","journal-title":"Curr Urol"},{"issue":"36","key":"938_CR73","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","volume":"32","author":"JT Wei","year":"2014","unstructured":"Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncology: Official J Am Soc Clin Oncol. 2014;32(36):4066\u201372.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"3","key":"938_CR74","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.eururo.2012.11.014","volume":"65","author":"GH Leyten","year":"2014","unstructured":"Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534\u201342.","journal-title":"Eur Urol"},{"key":"938_CR75","doi-asserted-by":"crossref","unstructured":"Opoku Mensah B, Fondjo LA. Urinary PCA3 a Superior Diagnostic Biomarker for Prostate Cancer among Ghanaian Men. Disease markers 2022;2022:1686991.","DOI":"10.1155\/2022\/1686991"},{"issue":"1131","key":"938_CR76","doi-asserted-by":"publisher","first-page":"20210413","DOI":"10.1259\/bjr.20210413","volume":"95","author":"S Ippoliti","year":"2022","unstructured":"Ippoliti S, Fletcher P, Orecchia L, Miano R, Kastner C, Barrett T. Optimal biopsy approach for detection of clinically significant prostate cancer. Br J Radiol. 2022;95(1131):20210413.","journal-title":"Br J Radiol"},{"key":"938_CR77","doi-asserted-by":"crossref","unstructured":"Osses DF, Arsov C, Schimm\u00f6ller L. Equivocal PI-RADS three lesions on prostate magnetic resonance imaging: risk stratification strategies to avoid MRI-Targeted biopsies. J Personalized Med 2020;10(4).","DOI":"10.3390\/jpm10040270"},{"issue":"2","key":"938_CR78","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/clinpract14020039","volume":"14","author":"E Bologna","year":"2024","unstructured":"Bologna E, Ditonno F. Tissue-Based genomic testing in prostate cancer: 10-Year analysis of National trends on the use of prolaris, decipher, promark, and oncotype DX. Clin Pract. 2024;14(2):508\u201320.","journal-title":"Clin Pract"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00938-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00938-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00938-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:06:32Z","timestamp":1759158392000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00938-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00938-1","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a review of previously published literature and does not report on or involve the use of any animal or human data or tissue.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain data from any individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}